Literature DB >> 15634903

Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.

Qian Gong1, Qinglin Ou, Shiming Ye, Wyne P Lee, Jennine Cornelius, Lauri Diehl, Wei Yu Lin, Zhilan Hu, Yanmei Lu, Yongmei Chen, Yan Wu, Y Gloria Meng, Peter Gribling, Zhonghua Lin, Kathy Nguyen, Thanhvien Tran, Yifan Zhang, Hugh Rosen, Flavius Martin, Andrew C Chan.   

Abstract

B cell immunotherapy has emerged as a mainstay in the treatment of lymphomas and autoimmune diseases. Although the microenvironment has recently been demonstrated to play critical roles in B cell homeostasis, its contribution to immunotherapy is unknown. To analyze the in vivo factors that regulate mechanisms involved in B cell immunotherapy, we used a murine model for human CD20 (hCD20) expression in which treatment of hCD20(+) mice with anti-hCD20 mAbs mimics B cell depletion observed in humans. We demonstrate in this study that factors derived from the microenvironment, including signals from the B cell-activating factor belonging to the TNF family/BLyS survival factor, integrin-regulated homeostasis, and circulatory dynamics of B cells define distinct in vivo mechanism(s) and sensitivities of cells in anti-hCD20 mAb-directed therapies. These findings provide new insights into the mechanisms of immunotherapy and define new opportunities in the treatment of cancers and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634903     DOI: 10.4049/jimmunol.174.2.817

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  171 in total

1.  Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice.

Authors:  Hans D Brightbill; Surinder Jeet; Zhonghua Lin; Donghong Yan; Meijuan Zhou; Martha Tan; Allen Nguyen; Sherry Yeh; Donnie Delarosa; Steven R Leong; Terence Wong; Yvonne Chen; Mark Ultsch; Elizabeth Luis; Sree Ranjani Ramani; Janet Jackman; Lino Gonzalez; Mark S Dennis; Anan Chuntharapai; Laura DeForge; Y Gloria Meng; Min Xu; Charles Eigenbrot; Wyne P Lee; Canio J Refino; Mercedesz Balazs; Lawren C Wu
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

2.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Authors:  Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

3.  Development of a novel long-lived immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic mouse model.

Authors:  Arutselvan Natarajan; Frezghi Habte; Sanjiv S Gambhir
Journal:  Bioconjug Chem       Date:  2012-06-11       Impact factor: 4.774

Review 4.  Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

Authors:  Mohammad Tabrizi; Cherryl Funelas; Hamza Suria
Journal:  AAPS J       Date:  2010-07-24       Impact factor: 4.009

5.  B-cell-targeted therapy for the fibrotic complications of systemic sclerosis.

Authors:  Robert Woodrick; John Varga
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

6.  Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus.

Authors:  Kai W Bekar; Teresa Owen; Robert Dunn; Travis Ichikawa; Wensheng Wang; Roger Wang; Jennifer Barnard; Sean Brady; Sarah Nevarez; Bruce I Goldman; Marilyn Kehry; Jennifer H Anolik
Journal:  Arthritis Rheum       Date:  2010-08

7.  B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity.

Authors:  Martin S Weber; Thomas Prod'homme; Juan C Patarroyo; Nicolas Molnarfi; Tara Karnezis; Klaus Lehmann-Horn; Dimitry M Danilenko; Jeffrey Eastham-Anderson; Anthony J Slavin; Christopher Linington; Claude C A Bernard; Flavius Martin; Scott S Zamvil
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

Review 8.  [Pemphigus. Model disease for targeted therapy].

Authors:  R Eming
Journal:  Hautarzt       Date:  2015-08       Impact factor: 0.751

9.  Induced resistance to ofatumumab-mediated cell clearance mechanisms, including complement-dependent cytotoxicity, in chronic lymphocytic leukemia.

Authors:  Nisar A Baig; Ronald P Taylor; Margaret A Lindorfer; Amy K Church; Betsy R LaPlant; Adam M Pettinger; Tait D Shanafelt; Grzegorz S Nowakowski; Clive S Zent
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

10.  Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy.

Authors:  Laura M Rogers; Sarah L Mott; Brian J Smith; Brian K Link; Deniz Sahin; George J Weiner
Journal:  Clin Cancer Res       Date:  2016-08-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.